... careful interpreta-tion of the results. For one, the rather low numbers andevents in the prior phase I trial may not reflect the true,i.e. potentially low efficacy of BEXIDEM. Secondly, thisphase ... ISRCTN35881130.IntroductionTURB is the therapeutic gold standard for non-muscleinvasive BC. Up to 50-70% of cases recur, rendering BCone of the most prevalent malignancies [1]. According to the respective guidelines the ... Dept. of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, GermanyFull list of author information is available at the end of the articleBurger et al. Journal of...